Jason Hanson is the founder of enGene. enGene has raised $135M in total funding. Latest round: Growth. Backed by Forbion Growth, BVF Partners, Omega Funds.
Jason Hanson is the CEO of enGene, a clinical-stage biotechnology company that develops non-viral gene therapies based on its proprietary dually derivatized chitosan (DDX) platform. The company's therapies are designed to be re-dosable, manufacturable at scale, and seamlessly integrated into community clinical practices. enGene is focused on building a multi-indication franchise and advancing its lead candidate, detalimogene voraplasmid (EG-70), for BCG-unresponsive, non-muscle invasive bladder cancer.
Full founder directory · Investor directory · Company funding database · Fundraising library